Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Status:	Recruiting
Conditions:	Skin and Soft Tissue Infections, Infectious Disease
Therapuetic Areas:	Dermatology / Plastic Surgery, Immunology / Infectious Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	7/4/2018
Start Date:	November 29, 2016
End Date:	December 31, 2018
Contact:	Clinical Trials Registration Team
Email:	IR-CTRegistration@allergan.com
Phone:	1-800-347-4500

A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

This study will evaluate a new critical pathway (use of guideline-based patient
identification criteria and for those who meet these criteria, use of dalbavancin) for the
treatment of ABSSSI compared to usual care.

Inclusion Criteria:

- Presents to the Emergency Department (ED) and meets the clinical definition for Acute
Bacterial Skin and Skin Structure Infections (ABSSSI)

- Known or suspected gram-positive infection.

Exclusion Criteria:

- Known or suspected gram-negative infections, anaerobic infections, or fungemia

- Known or suspected infections that are severe, life threatening or are not included in
the ABSSSI Food and Drug Administration (FDA) guidance

- Injection drug users with a fever

- Severe neurological disorder leading to immobility or confined to a wheelchair

- Bilateral Lower extremity involvement of the suspected infection.

We found this trial at

sites

Maricopa Medical Center

Phoenix, Arizona 85008

from

Phoenix, AZ